Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
EUR 18M - 18M
Notice Type:
Contract award notice
Published Date:
30 July 2021
Closing Date:
Location(s):
ES51 Cataluña (ES Spain/ESPAÑA)
Description:
Suministros agregados de medicamentos: adalimumab, etanercept, infliximab, rituximab, trastusumab

Suministros agregados de medicamentos: adalimumab, etanercept, infliximab, rituximab, trastusumab.

Suministros agregados de medicamentos: adalimumab, etanercept, infliximab, rituximab, trastusumab.

Awarded to:
Suministros agregados de medicamentos: adalimumab, etanercept, infliximab, rituximab, trastusumab
Accord Healthcare, S. L. U., Barcelona (ES)
Amgen, S. A., Barcelona (ES)
Biogen Spain, S. L., Madrid (ES)
Fresenius Kabi, S. A. U., Barcelona (ES)
Kern Pharma, S. L., Terrassa (ES)
Organon Salud, S. L., Madrid (ES)
7
Pfizer, S. L. U., Alcobendas (ES)
Suministros agregados de medicamentos: adalimumab, etanercept, infliximab, rituximab, trastusumab
Roche Farma, S. A., Madrid (ES)
Sandoz Farmacéutica, S. A., Madrid (ES)
Download full details as .pdf
The Buyer:
Instituto Catalán de la Salut — Centro Corporativo (ICS)
CPV Code(s):
33600000 - Pharmaceutical products